Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Open-label, Single-arm, Multicenter Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Refractory and Relapsed Multiple Myeloma

NCT03136653 is registered in ClinicalTrials.gov with Molecular Partners AG as lead sponsor.

NCT NCT03136653
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03136653 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Open-label, Single-arm, Multicenter Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Refractory and Relapsed Multiple Myeloma
Lead sponsor
Molecular Partners AG
Phase
Phase 1/2
Overall status
Completed
Start date
May 23, 2017
Completion date
January 13, 2021
Enrollment
33 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma in relapse